2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

partial or incomplete response. 43,44 Whether modifying
treatment for patients with disease that does not achieved
complete metabolic response will improve outcomes has yet
to be determined. Finally, the emergence of new biologic
Authors’ Disclosures of Potential Conflicts of Interest
Author
Employment or
Leadership
Positions
Consultant or
Advisory Role
Gilles Salles Calistoga
Pharmaceuticals;
Celgene;
Janssen-Cilag;
Roche
Hervé Ghesquières*
Emmanuel Bachy*
*No relevant relationships to disclose.
1. Pulte D, Gondos A, Brenner H. Expected long-term survival of older
patients diagnosed with non-Hodgkin lymphoma in 2008-2012. Cancer Epidemiol.
2012;36:e19-25.
2. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have
changed the survival of patients with follicular lymphoma. J Clin Oncol.
2005;23:8447-8452.
3. Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or
high-dose therapy with autotransplant at time of relapse in patients with
follicular lymphoma: A GELA study. J Clin Oncol. 2008;26:3614-3620.
4. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the
United States: first report of the national LymphoCare study. J Clin Oncol.
2009;27:1202-1208.
5. Bertoni F, Coiffier B, Salles G, et al. MALT lymphomas: pathogenesis
can drive treatment. Oncology. 2011;25:1134-1142, 1147.
6. Peinert S, Seymour JF. Indolent lymphomas other than follicular and
marginal zone lymphomas. Hematol Oncol Clin North Am. 2008;22:903-940.
7. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al. Clinical
stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by
the British National Lymphoma Investigation with radiotherapy alone as
initial therapy. Br J Cancer. 1994;69:1088-1093.
8. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II
low-grade follicular lymphoma? Results of a long-term follow-up study of
patients treated at Stanford University. J Clin Oncol. 1996;14:1282-1290.
9. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-
Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol.
2004;22:1454-1459.
10. Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients
with early stage low-grade follicular lymphoma treated with radiation: a
Surveillance, Epidemiology, and End Results database analysis. Cancer.
2010;116:3843-3851.
11. Friedberg J, Byrtek M, Link B, et al. Should radiation therapy (Xrt) be
the standard therapeutic approach for stage I follicular lymphoma (FL)? A
comparative effectiveness analysis of the National Lymphocare Study (Nlcs).
In: Internationational Conference on Malignat Lymphoma; 2011; Lugano;
2011;p. iv91.
12. Dreyling M, Ghielmini M, Marcus R, et al. Newly diagnosed and
relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 2011;22:vi59-63 (suppl 6).
13. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice
Guidelines in Oncology: Non-Hodgkin’s lymphomas. JNCCN. 2010;8:288-334.
14. Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local
control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother
Oncol. 2011;100:86-92.
15. Young RC, Longo DL, Glatstein E, et al. The treatment of indolent
lymphomas: watchful waiting v aggressive combined modality treatment.
Semin Hematol. 1988;25:11-16 (suppl 2).
16. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden
follicular lymphomas between an initial no-treatment policy, prednimustine,
or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes
Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin
Oncol. 1997;15:1110-1117.
17. Ardeshna KM, Smith P, Norton A, al. E. Long-term effect of a watch
and wait policy versus immediate systemic treatment for asymptomatic
492
therapies, such engineered monoclonal antibodies, 45 immunomodulatory
agents, 46 or kinase inhibitors, 47 represent
innovative options that might change the current treatment
landscape.
Stock
Ownership Honoraria
REFERENCES
Celgene;
Janssen-Cilag;
Pfizer; Roche
Research
Funding
SALLES, GHESQUIÈRES, AND BACHY
Expert
Testimony
Other
Remuneration
advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet.
2003;362:516-522.
18. Hainsworth JD, Burris HA, 3rd, Morrissey LH, et al. Rituximab
monoclonal antibody as initial systemic therapy for patients with low-grade
non-Hodgkin lymphoma. Blood. 2000;95:3052-3056.
19. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal
antibody) as single first-line therapy for patients with follicular
lymphoma with a low tumor burden: clinical and molecular evaluation. Blood.
2001;97:101-106.
20. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent
rituximab given at the standard schedule or as prolonged treatment in
patients with mantle cell lymphoma: a study of the Swiss Group for Clinical
Cancer Res (SAKK). J Clin Oncol. 2005;23:705-711.
21. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of
patients with follicular lymphoma receiving single-agent rituximab at two
different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28:4480-4484.
22. Ardeshna KM, Smith P, Qian W, et al. An intergroup randomised trial
of rituximab versus a watch and wait strategy in patients with stage II, III,
IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A
preliminary analysis. ASH Annual Meeting Abstracts. 2011;116 (abstr 6).
23. Ardeshna KM, Qian W, Stephens R, et al. Preliminary Results Of
Quality Of Life (Qol) Analyses From The Intergroup Phase III Randomised
Trial Of Rituximab Vs A Watch And Wait Approach In Patients With
Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma (FL). Ann
Oncol. 2011;22:iv88 (suppl 4).
24. Kahl BS, Hong F, Williams ME, et al. Results of Eastern Cooperative
Oncology Group Protocol E4402 (RESORT): a randomized phase III study
comparing two different rituximab dosing strategies for low tumor burden
follicular lymphoma. ASH Annual Meeting Abstracts. 2011:118 (suppl LBA-
6).
25. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy
with fludarabine followed by tositumomab and iodine I 131 tositumomab
for untreated follicular lymphoma. J Clin Oncol. 2005;23:5696-5704.
26. Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone
followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients
with follicular non-Hodgkin lymphoma trial: a phase II nonrandomised
trial (FLUMIZ). Lancet Oncol. 2008;9:352-358.
27. Link BK, Martin P, Kaminski MS, et al. Cyclophosphamide, vincristine,
and prednisone followed by tositumomab and iodine-131-tositumomab in
patients with untreated low-grade follicular lymphoma: eight-year follow-up
of a multicenter phase II study. J Clin Oncol. 2010;28:3035-3041.
28. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP
compared with cyclophosphamide, vincristine, and prednisone alone in patients
with previously untreated advanced follicular lymphoma. J Clin Oncol.
2008;26:4579-4586.
29. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2
years in patients with high tumour burden follicular lymphoma responding to
rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled
trial. Lancet. 2011;377:42-51.
30. Federico M, Luminari S, Dondi A, et al. R-CVP vs R-CHOP vs R-FM for
the initial treatment of patients with advanced stage follicular lymphoma.
Preliminary results of Foll05 Iil Trial. Ann Oncol. 2011;22:iv128 (suppl 4).
31. Nastoupil L, Sinha R, Byrtek M, et al. A comparison of the effectiveness